Loading stock data…
GUTS
$0.70+0.06 (+9.69%)
Market ClosedLast close May 1
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fractyl Health, Inc. in the Healthcare sector is trading at $0.70. The stock is currently near its 52-week low of $0.38, remaining 41.2% below its 200-day moving average. Technical signals show overbought RSI of 74 and bullish MACD crossover, explaining why GUTS maintains its current current market pressure. The Whystock Score of 10/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 74) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.70
Potential Upside
5%
Whystock Fair Value$0.73
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal d...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$92.18M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1490.32%
Volume
Today's trading volume
2.61M
Recent News
Fractyl Health, Inc. Common Stock Q4 2025 Earnings Call Summary
Moby summary of Fractyl Health, Inc. Common Stock's Q4 2025 earnings call
Fractyl Health Inc (GUTS) Q4 2025 Earnings Call Highlights: Navigating Financial Challenges ...
Despite a significant net loss, Fractyl Health Inc (GUTS) remains optimistic with strong cash reserves and promising regulatory feedback for its Revita device.
Fractyl Health Q4 Earnings Call Highlights
Fractyl Health (NASDAQ:GUTS) used its fourth-quarter and full-year 2025 results call to sharpen its investment narrative around Revita, its endoscopic procedure aimed at helping patients maintain weight loss after stopping GLP-1 drugs. Management said recent analyses of clinical data have clarified
H.C. Wainwright Maintains a Buy Rating on Fractyl Health, Inc. (GUTS) with an $8 Price Target
Fractyl Health, Inc. (NASDAQ:GUTS) is one of the 11 Best High Volume Penny Stocks to Buy Now. On March 17, 2026, H.C. Wainwright maintained a Buy rating on Fractyl Health, Inc. (NASDAQ:GUTS) with an $8 price target, addressing a sharp selloff following the company’s January data release. The firm said the update triggered a 65% […]
Fractyl Health, Inc. (GUTS) Moves to Buy: Rationale Behind the Upgrade
Fractyl Health, Inc. (GUTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.